Braftovi is a drug recommended for approval in Europe for the treatment of colorectal cancer.
The Committee for Medicines for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion on Braftovi as first-line treatment for patients with metastatic colorectal cancer.
The Committee for Medicines for Human Use (CHMP) of the European Medicines Agency (EMA) has officially recommended the approval of Braftovi (encorafenib) from Pierre Fabre Laboratories. This decision paves the way for the use of Braftovi in combination with cetuximab and Folfox as a first-line treatment for adult patients with metastatic colorectal cancer (mCRC) with the BRAFV600E mutation.
New breakthroughs in the treatment of metastatic colorectal cancer.
The CHMP's recommendation is based on results from the Phase III clinical trial called BREAKWATER. The study focused on evaluating the effectiveness of encorafenib in combination with standard therapy. The results showed that this combination regimen resulted in statistically superior improvements across key clinical parameters.
Notably, the study data showed a significant benefit in overall survival (OS). The use of Braftovi reduced the risk of death by up to 51% compared to traditional chemotherapy, with or without bevacizumab. This is considered a significant milestone in prolonging the lives of patients with this specific gene mutation.
Clinical efficacy as measured by real-world indicators.
According to the analysis report, the median progression-free survival (PFS) of patients using the new regimen reached 12.8 months. Meanwhile, the control group treated with conventional chemotherapy only achieved 7.1 months. The objective response rate (ORR) also showed a significant increase in the primary dataset analyzed.
| Clinical indicators | Braftovi + cetuximab + Folfox regimen | Control chemotherapy regimen |
|---|---|---|
| Progression-free survival (PFS) | 12.8 months | 7.1 months |
| Reduced risk of death (OS) | 51% | But |
If officially approved by the European Commission (EC) later this year, this combination would become the first and only targeted therapy for the B-Raf proto-oncogene (BRAF) for first-line treatment of patients with BRAFV600E-mutated mCRC in the European Union.
Commitment to innovation in the field of oncology
Eric Ducournau, CEO of Pierre Fabre Laboratories, commented that the CHMP's feedback is a significant step toward personalized treatment. He stressed that this milestone reflects the organization's commitment to advancing medical innovations to address unmet needs in cancer treatment.
Currently, the medical community in Europe is awaiting the final decision from the EC. The approval of Braftovi is expected to change the standard of healthcare, bringing new hope and improving the quality of life for patients with metastatic colorectal cancer and a poor prognosis due to gene mutations.
